Pharmaceutical cost containment with reference-based pricing: Time for refinements

CMAJ. Canadian Medical Association Journal

Volumn 167, Issue 11, 2002, Pages 1250-1251

  Schneeweiss, Sebastian ^a   Maclure, Malcolm ^a   Dormuth, Colin ^a   Avorn, Jerry ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRATE;

BUDGET; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; GOVERNMENT; HEALTH INSURANCE; HOSPITAL ADMISSION; HUMAN; INCOME; LONG TERM CARE; MEDICAL DECISION MAKING; MORTALITY; NOTE; PATIENT MONITORING; POLICY; POLITICS; PRESCRIPTION; PROSPECTIVE PRICING; TOXICITY;

EID: 0036435031     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (25)

1. Huskamp HA, Rosenthal MB, Frank RG, Newhouse JP. The Medicare prescription drug benefit: How will the game be played? Health Aff (Millwood) 2000;19(2):8-23.
2. Morgan S. Statistics and drug utilization: Are prescribing rates really that high? CMAJ 2001;165(11):1507-8.
3. Iglehart JK. Health policy 2001: Medicare and prescription drugs. N Engl J Med 2001;344:1010-5.
4. Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure: Is there anything to be learned? Pharmacoeconomics. In press.
5. Dickson M, Poullier JP. Prescription reimbursement systems in selected European countries. In: Huttin C, Bosanquet N, editors. The Prescription Drug Market: International Perspectives and Challenges for the Future. Vol. 17. Advanced series in management. Amsterdam: Elsevier Science Publishers; 1995. p. 107-38.
6. Tamblyn R, Laprise R, Hanley JA, Abrahamowicz M, Scott S, Mayo N, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 2001;285:421-9.
7. Soumerai SB, Avorn J, Gortmaker S, Ross-Degnan D. Payment restrictions for prescription drugs in Medicaid: Effects on therapy, cost, and equity. New Engl J Med 1987;317:550-6.
8. Soumerai SB, Ross-Degnan D, Avorn J, McLaughlin TJ, Choodnovskiy I. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med 1991;325:1072-7.
9. Soumerai SB, Ross-Degnan D, Gortmaker S, Avorn J. Withdrawing payment for nonscientific drug therapy. Intended and unexpected effects of a large-scale natural experiment. JAMA 1990;263:831-9.
10. Schneeweiss S, Soumerai SB, Glynn RJ, Maclure M, Dormuth C, Walker AM. Impact of reference-based pricing for angiotensin-converting-enzyme inhibitors on drug utilization. CMAJ 2002;166(6):737-45.
11. Grootendorst PV, Dolovich LR, O'Brien BJ, Holbrook AM, Levy AR. Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs. CMAJ 2001;165(8):1011-9.
12. Marshall JK, Grootendorst PV, O'Brien BJ, Dolovich LR, Holbrook AM, Levy AR. Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia. CMAJ 2002;166(13):1655-62.
13. Schneeweiss S, Soumerai SB, Maclure M. Reference drug pricing [letter]. CMAJ 2002;167(2):126-7.
14. Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB. Outcomes of reference drug pricing for angiotensin-converting enzyme inhibitors in British Columbia. N Engl J Med 2002;346:822-9.
15. Schneeweiss S, Maclure M, Soumerai SB. Prescription duration after drug copay changes in the elderly: Methodological aspects. J Am Geriatr Soc 2002;166:737-48.
16. Hazlet TK, Blough DK. Health services utilization with reference drug pricing of histamine2 receptor antagonists in British Columbia elderly. Med Care 2002;40:640-9.
17. Feldman SR, Fleischer AB, Chen GJ. Is prior authorization of topical tretinoin for acne cost effective? Am J Manag Care 1999;5:457-63.
18. Schneeweiss S, Schöffski O, Selke GW. What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution? Health Policy 1998;44(3):253-60.
19. Schwabe U, Paffrath D. Arzneimittelverordnungs-report 2001. Berlin: Springer; 2001.
20. Schöffski O. Consequences of implementing a drug budget for office-based physicians in Germany. Pharmacoeconomics 1996;10(Suppl 2):37-47.
21. Arzneien: Kräftiges plus im Oktober. Ärzte Zeitung 2001 Dec 12.
22. Avorn J, Soumerai SB. Improving drug-therapy decisions through educational outreach: A randomized controlled trial of academically based detailing. N Engl J Med 1983;308:1457-63.
23. Avorn J, Chen M, Hartley R. Scientific vs. commercial sources of influence on physician prescribing behavior. Am J Med 1982;73:4-8.
24. Coulter A. Fundholding general practitioners: Early successes - But will they last? BMJ 1992;304:397-8.
25. Maclure M, Carleton B, Schneeweiss S. Randomized delayed controls in health policy evaluation [letter]. JAMA 2000;284:2056-7.